Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239

1.

News Feature: Gene therapy successes point to better therapies.

Dolgin E.

Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):23866-23870. doi: 10.1073/pnas.1918306116. No abstract available.

2.

Unlocking the potential of vaccines built on messenger RNA.

Dolgin E.

Nature. 2019 Oct;574(7778):S10-S12. doi: 10.1038/d41586-019-03072-8. No abstract available.

PMID:
31619807
3.

Anti-CD3 drug keeps diabetes at bay.

Dolgin E.

Nat Biotechnol. 2019 Oct;37(10):1099-1101. doi: 10.1038/d41587-019-00025-4. No abstract available.

PMID:
31578500
4.

The bioengineering of cannabis.

Dolgin E.

Nature. 2019 Aug;572(7771):S5-S7. doi: 10.1038/d41586-019-02525-4. No abstract available.

PMID:
31462786
5.

'Psychological fear': MIT scientists of Chinese origin protest toxic US climate.

Dolgin E.

Nature. 2019 Jul;571(7764):157. doi: 10.1038/d41586-019-02063-z. No abstract available.

PMID:
31289386
6.

'Bubble boy' gene therapy reignites commercial interest.

Dolgin E.

Nat Biotechnol. 2019 Jul;37(7):699-701. doi: 10.1038/d41587-019-00015-6. No abstract available.

PMID:
31267099
7.

The secret social lives of viruses.

Dolgin E.

Nature. 2019 Jun;570(7761):290-292. doi: 10.1038/d41586-019-01880-6. No abstract available.

PMID:
31213694
8.

Anticancer autophagy inhibitors attract 'resurgent' interest.

Dolgin E.

Nat Rev Drug Discov. 2019 Jun;18(6):408-410. doi: 10.1038/d41573-019-00072-1. No abstract available.

PMID:
31160763
9.

The hunt for the lesser-known funding source.

Dolgin E.

Nature. 2019 Jun;570(7759):127-129. doi: 10.1038/d41586-019-01734-1. No abstract available.

PMID:
31160746
10.

Inner Workings: Genomics blazes a trail to improved cannabis cultivation.

Dolgin E.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8638-8640. doi: 10.1073/pnas.1904094116. No abstract available.

11.

Massive NIH-industry project opens portals to target validation.

Dolgin E.

Nat Rev Drug Discov. 2019 Feb 27. doi: 10.1038/d41573-019-00033-8. [Epub ahead of print] No abstract available.

PMID:
30936505
12.

How secret conversations inside cells are transforming biology.

Dolgin E.

Nature. 2019 Mar;567(7747):162-164. doi: 10.1038/d41586-019-00792-9. No abstract available.

PMID:
30858558
13.

First CD123-targeted drug approved after wowing in rare cancer.

Dolgin E.

Nat Biotechnol. 2019 Mar;37(3):202-203. doi: 10.1038/s41587-019-0056-8. No abstract available.

PMID:
30833771
14.

Sizzling interest in lab-grown meat belies lack of basic research.

Dolgin E.

Nature. 2019 Feb;566(7743):161-162. doi: 10.1038/d41586-019-00373-w. No abstract available.

PMID:
30755743
15.

Genomic focus brings tea research to the boil.

Dolgin E.

Nature. 2019 Feb;566(7742):S12-S13. doi: 10.1038/d41586-019-00400-w. No abstract available.

PMID:
30728517
16.

Responding to the call of home.

Dolgin E.

Nature. 2019 Feb;566(7742):143-145. doi: 10.1038/d41586-019-00448-8. No abstract available.

PMID:
30723358
17.

Publisher Correction: Radioactive drugs emerge from the shadows to storm the market.

Dolgin E.

Nat Biotechnol. 2019 Feb;37(2):193. doi: 10.1038/s41587-019-0030-5.

PMID:
30659240
18.

The brain's traffic problems.

Dolgin E.

Science. 2019 Jan 18;363(6424):221-223. doi: 10.1126/science.363.6424.221. No abstract available.

PMID:
30655425
19.

Lupus in crisis: as failures pile up, clinicians call for new tools.

Dolgin E.

Nat Biotechnol. 2019 Jan 3;37(1):7-8. doi: 10.1038/nbt0119-7. No abstract available.

PMID:
30605161
20.

Radioactive drugs emerge from the shadows to storm the market.

Dolgin E.

Nat Biotechnol. 2018 Dec 6;36(12):1125-1127. doi: 10.1038/nbt1218-1125. No abstract available. Erratum in: Nat Biotechnol. 2019 Feb;37(2):193.

PMID:
30520873
21.

Precision therapies take aim at non-Hodgkin's lymphoma.

Dolgin E.

Nature. 2018 Nov;563(7731):S46-S47. doi: 10.1038/d41586-018-07363-4. No abstract available.

PMID:
30429566
22.

What legal weed in Canada means for science.

Dolgin E.

Nature. 2018 Oct;562(7727):327-330. doi: 10.1038/d41586-018-07037-1. No abstract available.

PMID:
30333597
23.

The world at their feet.

Armitage C, Bourzac K, Dolgin E, Mallapaty S.

Nature. 2018 Sep;561(7723):S10-S15. doi: 10.1038/d41586-018-06622-8. No abstract available.

PMID:
30232442
24.

CD47 checkpoint data supercharge Stanford spinout IPO.

Dolgin E.

Nat Biotechnol. 2018 Aug 6;36(8):671-672. doi: 10.1038/nbt0818-671. No abstract available. Erratum in: Nat Biotechnol. 2018 Oct 11;36(10):915.

PMID:
30080839
25.

Alzheimer's disease is getting easier to spot.

Dolgin E.

Nature. 2018 Jul;559(7715):S10-S12. doi: 10.1038/d41586-018-05721-w. No abstract available.

PMID:
30046081
26.

How to start a lab when funds are tight.

Dolgin E.

Nature. 2018 Jul;559(7713):291-293. doi: 10.1038/d41586-018-05655-3. No abstract available.

PMID:
29988060
27.

There's no limit to longevity, says study that revives human lifespan debate.

Dolgin E.

Nature. 2018 Jul;559(7712):14-15. doi: 10.1038/d41586-018-05582-3. No abstract available.

PMID:
29968831
28.

First GPCR-directed antibody passes approval milestone.

Dolgin E.

Nat Rev Drug Discov. 2018 Jun 28;17(7):457-459. doi: 10.1038/nrd.2018.103. No abstract available.

PMID:
29950713
29.

When Huntington's disease comes early.

Dolgin E.

Nature. 2018 May;557(7707):S44-S45. doi: 10.1038/d41586-018-05178-x. No abstract available.

PMID:
29844553
30.

Scientists downsize bold plan to make human genome from scratch.

Dolgin E.

Nature. 2018 May;557(7703):16-17. doi: 10.1038/d41586-018-05043-x. No abstract available.

PMID:
29717256
31.

Industry embraces virtual trial platforms.

Dolgin E.

Nat Rev Drug Discov. 2018 Apr 27;17(5):305-306. doi: 10.1038/nrd.2018.66. No abstract available.

PMID:
29700498
32.

What lava lamps and vinaigrette can teach us about cell biology.

Dolgin E.

Nature. 2018 Mar 15;555(7696):300-302. doi: 10.1038/d41586-018-03070-2. No abstract available.

PMID:
29542707
33.

Bringing down the cost of cancer treatment.

Dolgin E.

Nature. 2018 Mar 8;555(7695):S26-S29. doi: 10.1038/d41586-018-02483-3. No abstract available.

PMID:
29517030
34.

Migraine drug race turns its final corner, FDA decisions in sight.

Dolgin E.

Nat Biotechnol. 2018 Mar 6;36(3):207-208. doi: 10.1038/nbt0318-207. No abstract available.

PMID:
29509726
35.

How going green can raise cash for your lab.

Dolgin E.

Nature. 2018 Feb 8;554(7691):265-267. doi: 10.1038/d41586-018-01601-5. No abstract available.

PMID:
29420504
36.

Nature's 10.

Ledford H, Castelvecchi D, Dolgin E, Reardon S, Gibney E, Phillips N, Witze A.

Nature. 2017 Dec 21;552(7685):315-324. doi: 10.1038/d41586-017-07763-y. No abstract available.

PMID:
29293224
37.

In good company.

Dolgin E.

Nature. 2017 Dec 7;552(7683):S24-S25. doi: 10.1038/d41586-017-07425-z. No abstract available.

PMID:
29219991
38.

The most popular genes in the human genome.

Dolgin E.

Nature. 2017 Nov 23;551(7681):427-431. doi: 10.1038/d41586-017-07291-9. No abstract available.

PMID:
29168817
39.

Age-related macular degeneration foils drugmakers.

Dolgin E.

Nat Biotechnol. 2017 Nov 9;35(11):1000-1001. doi: 10.1038/nbt1117-1000. No abstract available.

PMID:
29121027
40.

The young and the restless.

Dolgin E.

Nature. 2017 Nov 1;551(7678):S15-S18. doi: 10.1038/551S15a. No abstract available.

PMID:
29091602
41.

CRISPR hacks enable pinpoint repairs to genome.

Dolgin E.

Nature. 2017 Oct 25;550(7677):439-440. doi: 10.1038/550439a. No abstract available.

PMID:
29072279
42.

Genetics: The hexanucleotide hex.

Dolgin E.

Nature. 2017 Oct 18;550(7676):S106-S108. doi: 10.1038/550S106a. No abstract available.

PMID:
29045370
43.

Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Dolgin E.

Nat Biotechnol. 2017 Oct 11;35(10):891-892. doi: 10.1038/nbt1017-891. No abstract available.

PMID:
29019995
44.

Anti-inflammatory drug cuts risk of heart disease - and cancer.

Dolgin E.

Nat Rev Drug Discov. 2017 Sep 29;16(10):665-667. doi: 10.1038/nrd.2017.186. No abstract available.

PMID:
28959943
45.

Bioengineering: Doing without donors.

Dolgin E.

Nature. 2017 Sep 27;549(7673):S12-S15. doi: 10.1038/549S12a. No abstract available.

PMID:
28953861
46.

Blood feud erupts over Roche's bispecific antibody for hemophilia.

Dolgin E.

Nat Biotechnol. 2017 Sep 11;35(9):803-804. doi: 10.1038/nbt0917-803. No abstract available.

PMID:
28898214
47.

Profile: Michael Sporn: A legacy of greater knowledge.

Dolgin E.

Nature. 2017 Aug 9;548(7666):S16-S18. doi: 10.1038/548S16a. No abstract available.

PMID:
28792919
48.

Loxo TRK inhibitor data wows oncologists.

Dolgin E.

Nat Biotechnol. 2017 Aug 8;35(8):694-695. doi: 10.1038/nbt0817-694. No abstract available.

PMID:
28787403
49.

CAR-Ts move beyond B-cell cancers to myeloma.

Dolgin E.

Nat Biotechnol. 2017 Jul 12;35(7):599-601. doi: 10.1038/nbt0717-599. No abstract available.

PMID:
28700550
50.

News Feature: Radiation redux.

Dolgin E.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6416-6420. doi: 10.1073/pnas.1707802114. No abstract available.

Supplemental Content

Loading ...
Support Center